EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy

Mai Kawazoe iD, Kaichi Kaneko iD, Shotaro Masuoka, Soichi Yamada, Zento Yamada, Sei Muraoka iD, Karin Furukawa, Hiroshi Sato, Eri Watanabe, Keiko Koshiba, Izumi Irita, Miwa Kanaji und 3 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae810 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Mai Kawazoe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo 143-8541, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Bone Density Conservation Agents, Denosumab, Glucocorticoids. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: JSPS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Wnt/β-catenin signaling pathway is one of the pathogenic mechanisms of glucocorticoid-induced osteoporosis (GIOP). We previously reported the potential of inhibiting sclerostin as a treatment for GIOP.

Objective

To compare the efficacy of romosozumab (ROMO), a monoclonal antibody against sclerostin, with existing therapy for GIOP.

Methods

Patients with rheumatic diseases who had not previously received treatment for osteoporosis and were newly treated with prednisolone 15 mg/day or more were randomly assigned to receive ROMO, denosumab (DMAb), or bisphosphonates (BP). After the initiation of glucocorticoid therapy, we measured the bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip every 6 months and bone turnover markers every 3 months for 12 months.

Results

Eleven patients were assigned to the ROMO group, 14 to the DMAb group, and 14 to the BP group. The median [25th to 75th percentile] percent change in lumbar spine BMD from baseline at 12 months was the greatest in the ROMO group (ROMO: 8.6 [3.1-12.4]%, DMAb: 3.3 [1.5-6.2]%, BP: −0.4 [−3.4-1.1]%). Among bone formation markers, serum levels of bone alkaline phosphatase were slightly elevated in the ROMO group, whereas those of N-terminal propeptide of type I procollagen and osteocalcin decreased in all 3 groups; however, these changes were smaller in the ROMO group. Serum levels of bone resorption markers and a urine bone quality marker decreased in all groups.

Conclusion

Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients, suggesting that ROMO is effective for GIOP. Clinical trial number UMIN000037239

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalBone Density Conservation AgentsDenosumabGlucocorticoidsOsteoporosisRheumatic DiseasesRisedronic AcidAgedFemaleHumansMaleMiddle AgedBone DensityTreatment OutcomeAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

bisphosphonatesbone mineral densitydenosumabglucocorticoid-induced osteoporosisromosozumabsclerostin

Substanzen

Antibodies, MonoclonalBone Density Conservation AgentsDenosumabGlucocorticoidsRisedronic AcidromosozumabSOST protein, humanAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo 143-8541, Japan.
  • Department of Immunopathology and Immunoregulation, Toho University School of Medicine, Tokyo 143-8541, Japan.

ORCID-Profile: Mai Kawazoe, Kaichi Kaneko, Sei Muraoka, Takahiko Sugihara, Toshihiro Nanki

Förderung

  • JSPS

Zitieren

APA

Kawazoe, M., Kaneko, K., Masuoka, S., Yamada, S., Yamada, Z., Muraoka, S., Furukawa, K., Sato, H., Watanabe, E., Koshiba, K., Irita, I., Kanaji, M., Sugihara, T., Nishio, J., & Nanki, T. (2025). Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae810

Vancouver

Kawazoe M, Kaneko K, Masuoka S, Yamada S, Yamada Z, Muraoka S, et al. Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae810

BibTeX
@article{Kawazoe2025,
  author = {Kawazoe, Mai and Kaneko, Kaichi and Masuoka, Shotaro and Yamada, Soichi and Yamada, Zento and Muraoka, Sei and Furukawa, Karin and Sato, Hiroshi and Watanabe, Eri and Koshiba, Keiko and Irita, Izumi and Kanaji, Miwa and Sugihara, Takahiko and Nishio, Junko and Nanki, Toshihiro},
  title = {Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae810}
}
Kostenlos starten →